Technical Articles

Genetic variation

Advances and Prospects in Targeted Therapy for KRAS G12C-Mutated Non-Small Cell Lung Cancer

2026-03-03

The KRAS G12C mutation is one of the key driver gene alterations in non-small cell lung cancer, accounting for approximately 4% of NSCLC patients in Asia. Due to its unique molecular structural characteristics, KRAS G12C has long been considered an "undruggable" target, posing significant challenges in clinical treatment.

View details

Cancer
KRAS G12C & CRBN Binding Kit (GTP load)
Non-small cell lung cancer
Genetic variation

Total 1

Go to